TEL AVIV, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will deliver multiple presentations at the 2022 VEITH Symposium, which is being held November 15 – 19 in New York City.
Marvin Slosman, chief executive officer of InspireMD, stated, “We are very pleased to have such a notable presence at this year’s VEITH Symposium, which is among the most prestigious gatherings of vascular medicine specialists. There continues to be a growing body of clinical and safety data favoring CGuard EPS over competing stent platforms as well as open surgery, and gatherings such as VEITH are critical to raising awareness of this unique technology. We are grateful to all of the presenters who are participating on our behalf.”
Details of the presentations are as follows:
| Wednesday, November 16, 2022 | |
| Title: | Clinical Results of a MicroNet Covered Carotid-Stent (CGUARD): Analysis of 145 Patients at Two Sites: Advantages and Disadvantages |
| Presenter: | Christian Wissgott, MD, Christoph Kopetsch, MD and Reimer Andresen, MD |
| Time: | 5:30 PM – 5:35 PM ET |
| Location: | Trianon Ballroom, 3rd Floor |
| Friday, November 18, 2022 – Session 77: New Developments in the Treatment of Carotid Stenosis with Mesh Covered Stents and TCAR (Transcervical Carotid Artery Revascularization) | |
| Title: | Long-Term Results of Micromesh Stents Show Their Value in Carotid Artery Stenting (CAS): Are There Limitations: Do the Differences in the 3 Micromesh Stents Matter |
| Presenter: | Max Amor, MD |
| Time: | 7:53 AM – 7:58 AM ET |
| Location: | Grand Ballroom East, 3rd Floor |
| Title: | Update on Carotid and Other Uses of MicroNet-Covered Stents (C-Guard) in High-Risk Lesions and Aneurysms: What are the Long-Term Outcomes – and Are There Downsides |
| Presenter: | Piotr Musialek, MD, Dphil |
| Time: | 7:59 AM – 8:04 AM ET |
| Location: | Grand Ballroom East, 3rd Floor |
| Title: | New Multicenter Data Showing the Long-Term Value of the CGuard MicroNet Mesh Covered Stent for CAS in High-Risk Carotid Lesions (Thrombotic, Calcified and Symptomatic) From the FLOW-GUARD and Other Trials |
| Presenter: | D. Christopher Metzger, MD, Piotr Musialek, MD, Dphil |
| Time: | 8:05 AM – 8:10 AM ET |
| Location: | Grand Ballroom East, 3rd Floor |
| Title: | Results from a Multicenter Italian Study of the C-Guard Micromesh Stent for CAS: Advantages and Complications |
| Presenter: | Francesco Speziale, MD, Gianmarco de Donato, MD, Ashraf Mansour, MD, Pasqualino Sirignano, MD, Carlo Setacci, MD |
| Time: | 8:11 AM – 8:16 AM ET |
| Location: | Grand Ballroom East, 3rd Floor |
| Title: | Value of a Mesh Covered Stent with TCAR: Is It the Best of All Worlds: Limitations |
| Presenter: | Ralf R. Kolvenbach, MD |
| Time: | 10:48 AM – 10:53 AM ET |
| Location: | Grand Ballroom East, 3rd Floor |
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR.
We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts:
Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
craigs@inspiremd.com
Chuck Padala, Managing Director
LifeSci Advisors
646-627-8390
chuck@lifesciadvisors.com
investor-relations@inspiremd.com
